“The unique fusion of individual innovative technologies will provide a novel diagnostic tool leading to a better understanding of the underlying pathophysiology of rare anaemia.”

Lars Kaestner, Coordinator of CoMMiTMenT


The objective of CoMMiTMenT is to provide therapeutic interventions in the form of new medications either as proof-of-principle or as a tailored medical intervention to allow for the treatment of RA without major adverse effects.

Anaemia, which is defined as a haemoglobin concentration less than 11–13 g/dl depending on gender and age, affects 1.6 billion individuals worldwide. Approximately 10% of these individuals are affected by rare anaemia (RA). This disease group includes approximately 90 different types of red blood cell (RBC) diseases, of which 80% are hereditary or congenital in nature. As the pathophysiology of the majority of these RA is poorly understood, the appropriate treatment is often ineffective or even lacking. Although the total number of affected individuals is substantial, the diversity in the underlying causes has resulted in limited interest from the pharmaceutical industry.

The CoMMiTMenT partners are dedicated to systematically work through the list of anaemia-linked medical conditions to generate knowledge that will lead to effective targeted therapies.